To include your compound in the COVID-19 Resource Center, submit it here.

Molecular Partners reports Phase II data for MP0250 in MM

Molecular Partners AG (SIX:MOLN) reported data from seven evaluable patients with relapsed and refractory multiple myeloma (MM)

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE